Objective: To describe the process for establishment of a stand-alone laboratory dedicated to testing for Ebola virus disease (EVD).
and Marburg virus. Therefore, laboratory confirmation is needed for correct diagnosis.
Although no specific therapies for EVD are approved by regulating bodies such as the United States Food and Drug Administration (FDA), early diagnosis is essential to initiate supportive treatment before irreversible shock occurs and to prevent further spreading of the disease. Common laboratory findings in EVD include leukopenia, mild thrombocytopenia, elevation in serum transaminase levels, and abnormalities in coagulation and renal-injury markers. Several specific laboratory methods can detect Ebola virus infection, including antibody or antigen detection, conventional polymerase chain reaction (PCR) or real-time PCR (RT-PCR), and cell culture. 3, 5 RT-PCR has become the criterion standard method for EVD diagnosis during outbreak situations; it has high sensitivity and specificity in patients who have experienced symptoms for at least 3 days. 3, 6 The laboratory diagnosis and monitoring of EVD is critical and challenging in the care of patients, due to the risk of accidental infection within the laboratory. In October 2014, the Minnesota Hospital Association appointed our hospital, the University of Minnesota Medical Center-West Bank, as 1 of 4 EVD treatment centers in the state of Minnesota due to our expertise in critical care and infectious disease, as well as our willingness to serve as a centralized care facility for treatment of EVD. We designated an intensive care unit (ICU) within the hospital as an Ebola containment area and prepared a neighboring room to be a laboratory to support EVD testing. In this article, we describe the procedures for establishing that stand-alone laboratory dedicated to EVD testing.
Materials and Methods
Mirroring the approach of Emory University Hospital in Atlanta, GA, 7 we adopted a policy that no specimens would leave the containment unit for laboratory testing except inactivated microbiology slides or specimens collected for screening or confirmation of the presence of Ebola virus performed by the Minnesota Department of Health (MDH) and/or the Centers for Disease Control and Prevention (CDC). For all cases of suspected EVD, an epidemiologist at MDH would be contacted for consultation to determine whether EVD testing was warranted; if so, MDH would provide specific instructions for specimen collection and transport. Once the specimen arrived at MDH, RT-PCR testing would be performed, with an expected turnaround time of 4 to 6 hours. All specimens tested at MDH would be forwarded to the CDC for more extensive confirmatory testing, with an expected turnaround time of 1 day.
The laboratory space was designed to be a negative pressure room equipped with 2 level II biosafety cabinets (Image 1). We tracked the training of staff members using the customized Elsevier Performance Manager Learning Management System (LMS) (Elsevier Inc). A limited test menu ( Table 1 ) was developed after consultation with the team of Ebola care providers, CDC recommendations, and published test menus from other sites with EVD expertise. 7, 8 We based this menu on the expected clinical presentation and sequelae of EVD, as well as the need to rule out infectious diseases with similar clinical presentations.
Once the test menu was finalized, we selected several pointof-care (POC) devices and manual tests for the containment laboratory. Those devices/tests included multiple tests/ platforms already in use on-site for POC testing at our hospital, which could be implemented immediately without additional verification or validation: the Abbott i-STAT
Image 1
Photograph showing the set-up within the stand-alone Ebola laboratory. Two level II biosafety hoods were placed along the wall in a negative pressure room, with microbiology and manual testing performed in the hood on the left, and automated blood testing performed on the right. Due to its height, the Sysmex pocH-100i was determined to interfere with laminar flow in the hood, and therefore was placed in between the 2 hoods on a counter. 
Results
Planning for the Ebola testing laboratory initially began in the summer of 2014, with equipment acquisition occurring in September 2014. Most of the work involving laboratory renovation, planning, set-up, and training occurred in September 2014 and October 2014. Online training modules for laboratory staff were developed in-house by laboratory supervisors with extensive experience in education and training; participation was tracked using the Elsevier Performance Manager LMS. Laboratory supervisors created 12 detailed procedures and checklists for staff training, along with 22 different workflows ranging from specimen movement to specimen analysis. Laboratory staff members received additional electronic and hands-on training in taking personal protective equipment (PPE) on and off their bodies, and participated in Ebola patient simulations with nursing staff members. Initial training was completed before the initiation of laboratory operations in October 2014. The training modules and time required for completion are shown in Table 2 . A total of 17 lab technologists and technicians volunteered to be on call to staff the laboratory in 8-hour shifts, with 2 technicians per shift, because many of our procedures and protocols relied heavily on the buddy system (2 people operating as a single unit so that they can monitor and help each other), to ensure safe handling of specimens and correct putting on and taking off of PPE.
The expenses associated with the establishment of a standalone Ebola treatment patient unit and laboratory were substantial: the estimated cost to our hospital totaled approximately $921,000. This estimate encompassed all expenses related to remodeling and renovation, laboratory expenditures, equipment and material purchases, staff and physician labor costs, education, costs and treatment costs. Capital and labor costs specific to the laboratory are listed in Table 3 . This list of laboratory expenses does not include certain elements that are difficult to quantify. Those elements include delay of projects and validations associated with the operations of the main laboratory, and labor costs associated with the planning and preparation required to set up the laboratory quickly, including but not limited to additional meetings, conference calls, personnel training, creation of additional protocols and procedures, creation of educational training modules, selecting and purchasing instruments and reagents, validation of new instruments and assays, ongoing quality control and maintenance, creating and managing on-call schedules, maintenance of competency, and providing newsletter updates to laboratory staff members.
We purchased 3 new instruments for the containment laboratory (Abaxis Piccolo Xpress, Sysmex pocH-100i, and Helena Cascade), and the performance characteristics (accuracy, precision, and reportable range) of these moderate-complexity FDA-cleared assays were verified. On the Piccolo Xpress, we only planned to report on 2 analytes using the moderately complex MetLac cartridge, namely, magnesium and phosphorus. We compared the accuracy of the MetLac magnesium and phosphorus measurements with results on the central laboratory analyzer, the Siemens Vista, using 20 patient specimens, and found that the Piccolo Xpress met acceptable performance criteria ( Table 4) . The accuracy of the Sysmex pocH-100i was verified by measuring 30 specimens and comparing the results with those derived by the central laboratory instrument, the Sysmex XE-2100 (Sysmex Corporation). Correlation coefficients for white blood cells (WBC), red blood cells (RBC), hemoglobin, hematocrit, and platelets all exceeded 0.995 (Table 5) . For precision verification, our within-laboratory coefficients of variation (CVs) for magnesium, as measured on the Piccolo MetLac instrument using level 1 and 2 control materials, were 0% and 1.5% respectively. These values were well below the within-laboratory CVs published by the equipment manufacturer (3.4% and 2.6%, respectively). For phosphorus, our within-laboratory CV for the level-2 control was 1.7%, which was below the manufacturerreported precision value of 2.0%.
For the level-1 control, our within-laboratory precision value for phosphorus was 6.1%, which exceeded the withinlaboratory CV of 4.7% that was reported by the equipment manufacturer. Therefore, we calculated the upper verification limit (UVL) as recommended by Clinical and Laboratory Standards Institute (CLSI) guidelines, 14 which was determined to be 6.2%. Thus, our within-laboratory CV was below the UVL, which we decided was acceptable.
For the pocH-100i instrument, within-day and between-day precision experiments all yielded CVs all below the manufacturer-reported CVs for the pocH-100i. Therefore, we ruled that the degree of precision was acceptable for all analytes. For the Piccolo MetLac magnesium and phosphorus values, the reportable ranges were verified with 5 specimens spanning the measurement range, with excellent linearity and correlation with target values for both analytes (magnesium: y ¼ 0.9796x þ 0.0801, R ¼ 0.9999; phosphorus: y ¼ 1.0092x þ 0.1783, R ¼ 0.9999). On the pocH-100i, reportable ranges were verified with 4 specimens spanning the analytical measurement ranges for WBC, RBC, hemoglobin, hematocrit, and platelets, with all analytes demonstrating excellent linearity and correlation with target values (Table 6 ).
Because the Helena Cascade was removed from the market in September 2015 and is no longer available for purchase, we have not included data from our verification of this instrument. Currently, we are in the process of validating the Hemochron Signature Elite (Accriva Diagnostics) for partial thromboplastin time (PTT) and international normalized ratio (INR) testing. potassium, sodium and total carbon dioxide [TCO 2 ]) are available on the i-STAT (CHEM8þ cartridge) and Piccolo (Basic Metabolic Panel cartridge) instruments. Therefore, we performed method comparison studies between the Siemens Vista and both of the aforementioned POC instruments for these analytes to determine which one demonstrated the least overall bias compared with the Vista instrument ( Table 7) . The Piccolo showed greater bias compared with the i-STAT for BUN, sodium, potassium, glucose and TCO 2 , with the overall percentage bias for TCO 2 (12.2%) exceeding the acceptable performance goal of 610%. The i-STAT showed greater bias for chloride and creatinine, compared with the Piccolo. Therefore, we selected the i-STAT for basic metabolic panel measurements, due its better overall correlation with the Vista results. We did not directly compare ionized calcium results on the i-STAT and total calcium results on the Piccolo because those tests are different from one another.
The Comprehensive Metabolic Panel cartridge on the Piccolo instrument has a waiver from Clinical Laboratory Improvement Amendments (CLIA) regulations and so verification or validation is not required. Nevertheless, we performed a method comparison study to assess the applicability of our current reference intervals used on the Siemens Vista platform for 6 analytes that would be reported from this cartridge, namely, albumin, alkaline phosphatase, ALT, AST, total bilirubin, and total protein. All but albumin met the acceptable performance guidelines adapted from CLIA and the College of American Pathologists (CAP), with the overall percentage bias for albumin (10.7%) slightly exceeding the recommended acceptable performance of target value 610% ( Table 4) . Comparison data for albumin showed a largely constant positive bias of approximately 0.3 g per dL on the Piccolo. Per CLSI guideline C28-A3, method comparison results can be used to mathematically transform the current reference range to a new reference range for the new method if they are highly correlated. 15 Therefore, the upper and lower limits of the albumin reference range were increased by 0.3 for results reported on the Piccolo instrument.
Discussion
During the Ebola outbreak of 2014, clinical laboratories worldwide scrambled to set up appropriate facilities for handling clinical specimens in potential cases of EVD. Although EVD has been largely contained in West Africa, clinical laboratories must be better prepared for future outbreaks of Ebola and other infectious diseases. Therefore, it is imperative to establish processes and procedures for quarantined laboratory services. In this article, we have outlined our thorough process for establishment of a standalone laboratory, which can be used for the dedicated care of patients with EVD or other similar infectious diseases. Our Ebola containment facility and laboratory at the University of Minnesota-West Bank were recognized for their excellence when our hospital was selected as 1 of 9 special regional treatment centers in the United States for patients with Ebola or other highly infectious diseases. 16 A number of key principles guided us during the laboratory establishment process. Those principles included protection of patients, families, staff and communities; provision of laboratory support at any point of patient entry to the hospital; development of a single containment unit for patients under care; and development of a specialized expert team to provide ongoing testing validation.
Among the POC testing devices we evaluated for the Ebola laboratory, we discovered overlap in functionality between the i-STAT and Piccolo: both offer a basic metabolic panel cartridge. We compared the assay accuracy for the analytes that can be tested on both devices and determined that the i-STAT demonstrated the best overall performance for the basic metabolic panel analytes. The Piccolo is a popular instrument for Ebola laboratories, given its large chemistry testing menu; however, we recommend consideration of the Piccolo in conjunction with the i-STAT, based on our data that demonstrate greater bias with certain chemistry analytes on the Piccolo, such as BUN, sodium, potassium, glucose, and TCO 2 .
In summary, establishment of a stand-alone unit and laboratory dedicated to care of patients with EVD minimizes the risk of spreading EVD among hospital patients and employees. Once established, the laboratory facility may be used for future infectious disease outbreaks, with reassessment of the testing menu and instrumentation for new infectious agents based on their clinical presentation and on patient needs. Risk assessment, instrument validation, and employee training are major components that contribute to the success of establishing such a laboratory. LM
